Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.
Merck KGaA, Darmstadt, Germany, agrees to acquire Silence Therapeutics for roughly $1.3 billion, gaining a siRNA asset, ...
Foundayo’s EU backing, Enspryng for TED, Gilead’s masked TCE deal, FDA’s rare disease reset, and Bausch + Lomb’s new interim ...
FDA’s conditional approval of Jemperli (dostarlimab-gxly) rests on a single-arm phase 2 trial, with independent-review data ...
Hansoh Pharmaceutical Group Co., Ltd. announced it has entered into a strategic collaboration and license agreement with Roche covering a broad portfolio of antibody-drug conjugat ...
Pharmaceutical Executive spoke with John Stanford, executive director at Incubate, about the current status of MFN and how ...
AstraZeneca has signed a drug discovery collaboration and licensing agreement with insitro to apply artificial intelligence ...
The FDA approved Enspryng (satralizumab) on Oct. 16 for adults with thyroid eye disease (TED). 1 Roche describes the ...
In today’s Pharmaceutical Executive Daily, Gilead and Vir Biotechnology enter a collaboration worth up to $1.87 billion to ...
Why “we’re safe” is the most dangerous assumption in medical benefit commercialization. There is a conversation happening in boardrooms and brand planning cycles across the pharmaceutical industry ...
President Trump’s Most-Favored Nation (MFN) initiative continues to impact the industry. Most recently, the deadline passed ...
Pharmaceutical Executive spoke with Marc Wagner, an FDA and life sciences attorney at Fox Rothschild, about the manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results